Cannabis Therapy Corp. Appoints Science Pioneer Dr. Cohava Gelber to Board
Company Appointment Demonstrates Commitment to Scientific Excellence
PR-Inside.com: 2014-04-15 14:48:01
NEW YORK, NY -- (Marketwired) -- 04/15/14 -- Cannabis Therapy Corp. (OTCQB: CTCO) (the "Company") a development stage enterprise focused on the business of manufacturing and marketing pharmaceutical level products containing phytocannabinoids, an abundant and pharmaceutically active component of cannabis, for the treatment of various conditions and diseases, is very pleased to confirm the expert services of Dr. Cohava Gelber through her appointment to its growing Board of Directors.
Cohava Gelber, PhD, MBA, is an executive with over 25 years of experience in discovery and development of immune therapeutics and diagnostics for cancer, autoimmune disease, allergies and infectious diseases. Dr. Gelber held various executive positions in academia (Duke University) and biopharmaceutical companies (ImmuLogic Pharmaceutical Corporation, Molecular Discoveries and MannKind Corporation). Throughout her accomplished career, Dr. Gelber has pioneered and built various science companies, departments and proprietary platform technologies.
Dr. Gelber has recently launched Caerus Discovery, LLC (CDL) with support from Biowa/ Kyowa Hakko Kirin and ImmunoCellular Therapeutics, Inc. CDL 's mission is to discover and develop new antibody-based therapeutics. Prior to founding CDL, Dr. Gelber served as the Chief Scientific & Technology Officer of ATCC (2005-2010), VP of R&D for MannKind Corp -- a public company developing therapeutics for diabetes, cancer and autoimmune diseases (2001-2005). She was responsible for non-clinical development and clinical immune safety of drugs from pre IND through phase III clinical trials. Dr. Gelber published numerous scientific manuscripts and textbook chapters and she is the inventor of 11 granted patents and 57 patent applications. Dr. Gelber is board member of Etubics, Serpin Pharma and Caerus Discovery and on the Scientific Advisory Board of George Mason University, Libraries, NeuroQuest, MicroVax and Immuno Cellular Therapeutics. Dr. Gelber received her Ph.D. from the Weizmann Institute, her MBA degree from Cornell University and post doctorate training at Stanford University.
Cannabis Therapy Corp President & CEO Soren Mogelsvang comments, "We are delighted to inform the public of this important appointment today. The proven scientific input and extraordinary visionary capabilities Dr. Gelber brings to our Company signals a clear message of our intent to create a high quality science-based enterprise focused on value generation in this rapidly growing sector. I thank our newest Director for joining with us at this timely juncture as we move ahead quickly to achieve our aims."
Additional details of the Company's business, finances, appointments and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer with the Securities and Exchange Commission ("SEC") available at www.sec.gov : www.sec.gov/
. For more information please visit www.cannabistherapy.com : www.cannabistherapy.com/
About Cannabis Therapy Corp.
Cannabis Therapy Corp. aims to develop and market safe, phytocannabinoid-based medicinal products and to apply rigorous manufacturing and quality control standards to become a global leader in the research, development, manufacturing, testing and marketing of cannabinoid ingredients and therapies. For more information visit www.cannabistherapy.com : www.cannabistherapy.com/
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the availability of additional funding; and the Company's business, product development, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.
ON BEHALF OF THE BOARD,
Soren Mogelsvang, President & CEO
Cannabis Therapy Corp.
Add to Digg : digg.com/submit?phase=2&url= www2.marketwire.com/mw/release_html_b1?release_id=1106876
Bookmark with del.icio.us : del.icio.us/post?v=4&noui&jump=close&url= www2.marketwire.com/mw/release_html_b1?release_id=1106876
Add to Newsvine : www.newsvine.com/_tools/seed&save?u= www2.marketwire.com/mw/release_html_b1?release_id=1106876
For additional information, please contact:
Cannabis Therapy Corp. Investor Relations
T: +1 (800) 713-9091